Modelling the costs and benefits of an mRNA compared to a DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada

Cases of cervical cancer in Canada have decreased recently as a result of cytology-based screening programs. However, cervical cancer remains a relatively common and preventable cause of cancer in women. As cervical cancer is primarily caused by persistent genital infection with high-risk (HR) human papillomaviruses, Ontario Health has been evaluating implementing HPV-based testing in cervical screening.

As the type of HR-HPV test used in a cervical screen program can impact costs and resources, Aquarius Population Health developed a decision tree model to compare the use of the Aptima mRNA HR-HPV assay to a DNA HR-HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada.

Results found for women aged 30-65 years screened in Ontario, using an mRNA versus a DNA HR-HPV assay would save over $4M CAD and avoid roughly 11,000 unnecessary colposcopies, 15,000 HPV tests and 40,000 cytology tests.

Continue reading

Using an mRNA versus DNA test in the English cervical screening programme can save £15m annually and reduce unnecessary testing

The results of our economic evaluation comparing the use of mRNA and DNA assays in screening for cervical cancer in England were published in BMJ Open and are now available online. Results show large cost savings from avoiding unnecessary testing and follow-up, which can benefit women and healthcare services.

Continue reading

Improving patient care with rapid point of care tests

Dr Elisabeth Adams, Managing Director of Aquarius Population Health, presented on opportunities for rapid tests in influenza and HPV at international conferences in June.

This has been a busy week for the Aquarius Population Health team. We had two posters at the Society for Medical Decision Making in London (12-15th June), which Elisabeth presented. The posters showcased results from two studies we have done looking at the impact of implementing a rapid near-patient test for influenza and RSV. This was a collaborative project with Enigma Diagnostics and Guy’s and St Thomas’ NHS Trust. Results indicated that a rapid test could improve clinical management of patients with influenza, and could save commissioners money. It also illustrated how a rapid test could prevent unnecessary isolation bed days compared to current practice (presumptive isolation while waiting for results of the standard laboratory test results for influenza).

Continue reading

Rapid on-demand testing of HPV and cervical cancer prevention: IPV Conference in Lisbon

Our managing director, Dr Elisabeth Adams, is presenting two posters at the 30th annual International Papillomavirus Conference  in Lisbon, Portugal.  The first poster, “Exploring the value of a rapid, on-demand test for the detection of human papillomavirus”, is a detailed look at the current patient pathways for cervical screening programmes, and key opinion leaders’ views on the impact a rapid diagnostic would have on the health and overall wellbeing of women.

Continue reading